you are viewing a single comment's thread.
No good reason.As long as J&J management stays silent on earnings prospects and the status of DE stent sales, this stock will drop.
Rumor pushing stock down is that FDA is going to call meeting to re-evaluate the stents. Apparently, one hospital that has been using them has had major problems.
Stocks run in cycles and the market makers need to make their money. This company is very solid and 45-48 might be a good entry point. One consideration are the prices in Canada, which can affect pharma profits.
see my answer at 10 05 am